Humanigen, Inc., a biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ entered into an agreement with PCI Pharma Services (PCI), a global contract development manufacturing organization (CDMO), to provide importation, release and commercialization services in the UK for lenzilumab. Under the agreement, PCI will purchase lenzilumab for resale and distribution in the event a Conditional Marketing Authorization is received in the UK for use...